Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Limitless Life Nootropics

limitlesslifenootropics.com ↗
Founded: 2019 HQ: Gulf Breeze, FL Last reviewed: February 20, 2026
C
Overall Grade
Transparency 45/100
Testing 50/100
Pricing 55/100
Reputation 60/100
Compliance 45/100
Publishes COA Yes
Third-Party Testing Yes
FDA Warning Letters 0
Product Types injectable, lyophilized-powder, research-chemical

Limitless Life Nootropics

Overview

Limitless Life Nootropics (now branding as “Limitless Biotech”) is a Florida-based vendor that has grown into one of the more prominent US peptide suppliers, particularly within Facebook biohacking communities. The company claims US-based GMP manufacturing, third-party testing, and has cultivated a strong community presence through social media groups and direct owner engagement. However, significant quality inconsistencies across product lines and payment method red flags warrant careful scrutiny.

What We Found

Testing & Quality (Score: 55/100)

Finnrick Analytics data reveals a split personality:

  • BPC-157: Finnrick B (“Good”) — 6 samples tested (Feb–Sept 2025), average score above 6.0, no score below 5.0
  • CJC-1295: Finnrick D (“Poor”) — 8 samples tested (Feb 2025), average score above 4.0 but consistently lower
  • Ipamorelin: Finnrick D (“Poor”) — 4 samples tested (Feb 2025), same pattern

This product-by-product inconsistency is a significant concern. A vendor can score well on one peptide while delivering substandard quality on others, and buyers have no way to know without independent testing. The company claims all products undergo third-party testing and COAs are available, but the Finnrick data suggests quality control varies substantially by compound.

Transparency (Score: 50/100)

The company publicly emphasizes third-party testing and COA availability, which is positive. Website recently rebranded with professional presentation claiming US GMP manufacturing. However, specific lab partners are not named on-site, and the Finnrick discrepancy between products raises questions about supply chain consistency.

Pricing (Score: 45/100)

Pricing is on the higher end of the grey market. Multiple customers note products are more expensive than competitors for equivalent compounds. The premium would be justified by consistently superior testing, but the Finnrick D ratings on CJC-1295 and Ipamorelin undercut that value proposition.

Reputation (Score: 60/100)

Genuinely mixed:

  • Trustpilot: 3.7/5 from 148 reviews — polarized between enthusiastic long-term customers and frustrated newer buyers
  • BBB: Accredited as “Live Limitless LLC” with mixed reviews. Complaints include products arriving empty, unresponsive customer service, and products described as “placebos”
  • Facebook groups: Strong community presence, with the owner actively engaging. However, one BBB reviewer noted coordinated review campaigns (“nearly EVERY review appeared just two days ago”)
  • Customer service experiences range from “owner personally resolved my issue” to “CSR Brian was snarky and condescending”

Compliance (Score: 50/100)

Standard “research use only” disclaimers. Payment methods are a notable concern: the company accepts Zelle, Revolut, and CashApp — all of which offer minimal buyer protection and make chargebacks difficult. BBB complaints specifically cite Cash App payments as a barrier to dispute resolution. No known FDA enforcement actions, but payment methods common to grey-market operations raise compliance questions.

The PeptideExaminer Verdict

Limitless Life Nootropics delivers genuinely good BPC-157 (Finnrick B) but falls short on other compounds (CJC-1295 and Ipamorelin both Finnrick D). The community engagement is authentic and the owner’s accessibility is unusual for this market. But product-line inconsistency, premium pricing, limited payment protections, and polarized customer experiences prevent a higher grade. If you’re buying BPC-157 specifically, the Finnrick data is reassuring; for other compounds, proceed with caution.

Grade: C

CategoryScoreWeightWeighted
Transparency5020%10.0
Testing5525%13.75
Pricing4515%6.75
Reputation6020%12.0
Compliance5020%10.0
Total52.5 → C

Sources: Finnrick Analytics (finnrick.com), Trustpilot, BBB.org (Live Limitless LLC), limitlesslifenootropics.com